Wellington Management Group Portfolio holdings
Wellington Management Group, founded in 1928 by Walter L. Morgan and headquartered in Boston, Massachusetts, is one of the world’s largest independent asset management firms, overseeing trillions in assets for a diverse client base including pension funds, endowments, and mutual fund investors. Renowned for its active management approach, Wellington offers a broad range of investment strategies across equities, fixed income, multi-asset, and alternative investments, emphasizing deep research and long-term partnerships with clients. The firm gained early fame for launching the Wellington Fund, one of the first balanced mutual funds, and has since maintained a reputation for disciplined, collaborative portfolio management. With a global presence and a focus on customized solutions, Wellington remains a trusted name in institutional and retail investing.
Top Buys
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$1.71B |
| 2 |
Eli Lilly
LLY
|
+$1.55B |
| 3 |
Tesla
TSLA
|
+$1.14B |
| 4 |
Boeing
BA
|
+$935M |
| 5 |
TE Connectivity
TEL
|
+$910M |
Top Sells
| 1 |
Apple
AAPL
|
+$1.79B |
| 2 |
Visa
V
|
+$1.57B |
| 3 |
General Dynamics
GD
|
+$1.55B |
| 4 |
Morgan Stanley
MS
|
+$1.29B |
| 5 |
Exelon
EXC
|
+$1.15B |
Sector Composition
| 1 | Technology | 24.19% |
| 2 | Healthcare | 17.87% |
| 3 | Financials | 14.67% |
| 4 | Consumer Discretionary | 10.1% |
| 5 | Industrials | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1551
Voyager Therapeutics
VYGR
$232M
| $1.48M | ﹤0.01% |
261,251
+31,882
| +14% | +$181K |
|
1552
Altimmune
ALT
$321M
| $1.48M | ﹤0.01% |
205,233
+8,001
| +4% | +$57.7K |
|
1553
CorMedix
CRMD
$966M
| $1.45M | ﹤0.01% |
178,786
-2,162
| -1% | -$17.5K |
|
1554
InterDigital
IDCC
$8.33B
| $1.44M | ﹤0.01% |
7,439
-148,261
| -95% | -$28.7M |
|
1555
Rhythm Pharmaceuticals
RYTM
$6.39B
| $1.43M | ﹤0.01% |
25,555
-2,161
| -8% | -$121K |
|
1556
Ferrovial SE
FER
$41.3B
| $1.42M | ﹤0.01% |
33,774
+813
| +2% | +$34.2K |
|
1557
Affiliated Managers Group
AMG
$6.71B
| $1.42M | ﹤0.01% |
7,659
-6,137
| -44% | -$1.13M |
|
1558
Tourmaline Bio
TRML
$1.22B
| $1.39M | ﹤0.01% |
68,599
+2,858
| +4% | +$58K |
|
1559
Kiniksa Pharmaceuticals
KNSA
$2.75B
| $1.38M | ﹤0.01% |
69,813
+22,096
| +46% | +$437K |
|
1560
Consumer Discretionary Select Sector SPDR Fund
XLY
$24.1B
| $1.38M | ﹤0.01% |
6,151
-745
| -11% | -$167K |
|
1561
Annexon
ANNX
$266M
| $1.38M | ﹤0.01% |
268,166
+4,806
| +2% | +$24.7K |
|
1562
MindMed
MNMD
$718M
| $1.35M | ﹤0.01% |
194,491
+8,769
| +5% | +$61K |
|
1563
Aecom
ACM
$16.8B
| $1.35M | ﹤0.01% |
12,602
+603
| +5% | +$64.4K |
|
|
RDUS
1564
DELISTED
Radius Recycling
RDUS
| $1.34M | ﹤0.01% |
88,129
+760
| +0.9% | +$11.6K |
|
1565
Rogers Communications
RCI
$19.3B
| $1.33M | ﹤0.01% |
43,424
+21,226
| +96% | +$652K |
|
1566
Thomson Reuters
TRI
$78B
| $1.33M | ﹤0.01% |
8,298
-7,847
| -49% | -$1.26M |
|
1567
Astria Therapeutics
ATXS
$419M
| $1.32M | ﹤0.01% |
148,049
+550
| +0.4% | +$4.92K |
|
1568
EyePoint Pharmaceuticals
EYPT
$920M
| $1.32M | ﹤0.01% |
177,316
+5,552
| +3% | +$41.4K |
|
1569
NextDecade
NEXT
$1.79B
| $1.32M | ﹤0.01% |
171,169
+67,571
| +65% | +$521K |
|
1570
Tyra Biosciences
TYRA
$667M
| $1.32M | ﹤0.01% |
94,859
+4,034
| +4% | +$56.1K |
|
1571
Dianthus Therapeutics
DNTH
$1.2B
| $1.32M | ﹤0.01% |
60,337
+6,552
| +12% | +$143K |
|
1572
Gildan
GIL
$8.03B
| $1.31M | ﹤0.01% |
27,757
-1,967
| -7% | -$92.5K |
|
1573
Pennant Group
PNTG
$884M
| $1.3M | ﹤0.01% |
48,853
+6,753
| +16% | +$179K |
|
1574
Emergent Biosolutions
EBS
$434M
| $1.29M | ﹤0.01% |
135,342
-947
| -0.7% | -$9.05K |
|
1575
Humacyte
HUMA
$233M
| $1.29M | ﹤0.01% |
254,735
+324
| +0.1% | +$1.64K |
|